| Methods |
4‐week placebo run‐in; inclusion criteria= supine and standing clinic DBP >/= 95 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Trandolapril 2 mg: n=42(31 males,11 females); mean age=51.4(9.7) years; baseline supine SBP=159.8(12.8) mm Hg, DBP=102.4(5.1) mm Hg, HR=72.1(8.3) bpm;
Placebo: n=20(15 males, 5 females); mean age=51.1(7.6) years; baseline supine SBP=158.0(13.5) mm Hg, DBP=102.3(4.8) mm Hg, HR=73.9(8.3) bpm |
| Interventions |
Trandolapril 2 mg once daily;
Placebo;
administered at approximately 9 AM |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
Trough supine HR;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SE reported, calculated endpoint SD from N and SE; imputed endpoint SD for SD of change; BP data from Table II, p. 62D; duplicate publication=Ravogli 94; Jadad score=3; funding source= Roussel Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
